These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24064287)

  • 1. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy.
    Yang JJ; Tsai MS; Sun HY; Hsieh SM; Chen MY; Sheng WH; Chang SC
    J Microbiol Immunol Infect; 2015 Apr; 48(2):130-6. PubMed ID: 24064287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical manifestations of treatment-naive patients with acquired immunodeficiency syndrome and responses to highly active antiretroviral therapy in the Taipei Veterans General Hospital: a 5-year prospective study.
    Hsu SF; Yang SP; Chan YJ; Wang YW
    J Microbiol Immunol Infect; 2011 Jun; 44(3):198-203. PubMed ID: 21524614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained favourable HIV viral load response in South African patients during concomitant HAART and cancer therapy.
    Musyoki AM; Msibi TL; Motswaledi MH; Selabe SG; Mphahlele MJ
    J Med Virol; 2015 Feb; 87(2):192-8. PubMed ID: 25156795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune diabetes in HIV-infected patients on highly active antiretroviral therapy.
    Takarabe D; Rokukawa Y; Takahashi Y; Goto A; Takaichi M; Okamoto M; Tsujimoto T; Noto H; Kishimoto M; Kaburagi Y; Yasuda K; Yamamoto-Honda R; Tsukada K; Honda M; Teruya K; Kajio H; Kikuchi Y; Oka S; Noda M
    J Clin Endocrinol Metab; 2010 Aug; 95(8):4056-60. PubMed ID: 20484483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical significance of serum autoantibodies and HLA-B(27) molecule testing in Uygur patients with human immunodeficiency virus infection].
    Chen XM; Luo CN; Wu LJ; Shi YM; Wu X; Meng XY; Lei X; Liu Y; Reyimujiang Y; Gulimire K; Wang TY; Xia FF
    Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):195-199. PubMed ID: 32146745
    [No Abstract]   [Full Text] [Related]  

  • 12. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era.
    Nguyen BY; Reveille JD
    Curr Opin Rheumatol; 2009 Jul; 21(4):404-10. PubMed ID: 19444116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
    Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
    Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
    Benveniste O; Flahault A; Rollot F; Elbim C; Estaquier J; Pédron B; Duval X; Dereuddre-Bosquet N; Clayette P; Sterkers G; Simon A; Ameisen JC; Leport C
    J Infect Dis; 2005 May; 191(10):1670-9. PubMed ID: 15838794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV infection and rheumatic diseases--autoimmune mechanisms in immunodeficient hosts.
    Weyand CM; Goronzy JJ
    Z Rheumatol; 1992; 51(2):55-64. PubMed ID: 1535472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.